Is Wegovy Worth the Money? Here's What the Evidence Actually Says

Step 1: Understand what you're actually paying for

Wegovy is not a supplement or an appetite-suppressant you pick up off a shelf. It is a GLP-1 receptor agonist (semaglutide at prescription strength) that works by mimicking a gut hormone your body already produces. After each weekly dose, your brain receives appetite signals earlier than usual, your stomach empties more slowly, and food cravings reduce. The mechanism is biological, not motivational. How Wegovy works in the body is covered in more detail if you want to understand the pharmacology before deciding.

That mechanism is also why the cost question is more complicated than a straight price comparison. You are paying for a clinically regulated medicine that has gone through large-scale trials, plus the prescriber's assessment that clears it for you specifically, plus ongoing clinical oversight. On any legitimate private service, the price should reflect all of those components. On services where the headline figure looks strikingly low, it usually means some of those components are charged separately, or, in the worst cases, are not present at all.

Pull the pen out of the fridge on the same day each week, recap it, put it back. That routine is straightforward. What is less straightforward is knowing whether the pen you received came through a licensed UK supply chain and was prescribed by someone who actually reviewed your medical history. That is part of what you are paying for.

Step 2: Look at what the trial data shows, and what it doesn't

The clinical evidence for semaglutide at weight-management doses is substantial. The STEP 1 trial, published in the New England Journal of Medicine, followed adults with obesity over 68 weeks and reported an average body-weight reduction of around 15% at the 2.4mg dose alongside lifestyle changes. For someone weighing 110kg at the start, that is roughly 16–17kg. For a condition as complex as obesity, trial results of that scale are genuinely significant.

The evidence grew further in 2026, when the MHRA approved a 7.2mg maintenance dose, a single-dose pen approved on 14 April 2026, for adults with a BMI of 30 or above. Trials at that dose reported around 20.7% average weight loss over 72 weeks, which narrows the gap with tirzepatide considerably. Whether that higher dose is appropriate for a given person is a clinical decision, not one to make based on trial averages alone.

What the evidence does not tell you is what your individual result will be. Responses vary. Some people lose significantly more than the trial average; others less. The trial data is the best guide available, and it is encouraging, but results depend on adherence, lifestyle changes alongside treatment, and individual biology. If you are also thinking about whether using Wegovy for one month is worth it, that page goes further into the outcome data and what a shorter period of treatment can realistically deliver. A longer look at whether Wegovy is worth it specifically for weight loss goes further into the outcome data if you want more detail.

Step 3: Weigh the cost against what's genuinely included

Private Wegovy costs in the UK have shifted since Eli Lilly changed list pricing in 2025. Across providers, typical monthly costs since then have ranged from roughly £149 to £375, depending on the dose you're on and the service you use. That is a wide range, and the gap is not random. It reflects differences in what is and isn't included.

Some providers charge a headline medicine price plus separate fees for the consultation, the prescription, delivery, and aftercare calls. Others, including nume, bundle everything into one price: the clinical consultation, prescriber review, the medicine itself, next-working-day tracked delivery, and access to clinical support seven days a week. Neither model is hidden, but you do need to read the small print before comparing figures.

The Wegovy treatment page on the nume site sets out current pricing clearly. One contextual note worth reading before comparing costs is this one on whether Wegovy is worth it, which looks at the value question from a slightly different angle. For a prescription medicine, the cheapest listing answers the wrong question, what matters is whether the supply chain is licensed, the prescriber is registered, and the clinical review is real.

The MHRA has warned repeatedly about counterfeit weight-loss pens sold online, including fake pens that have contained insulin. Buying at a price that looks too good to be worth investigating is one of the clearest risk signals. You can verify any online pharmacy on the GPhC register before committing to treatment.

Step 4: Factor in the support around the medicine

Wegovy works best as part of a structured approach that includes dietary changes and increased activity, that is what both the licence and the NICE guidance reflect. NICE's appraisal of semaglutide (TA875) recommends it for use alongside a specialist weight management programme. The medicine reduces appetite; what you do with that reduced appetite shapes your result.

This matters financially too. A period of treatment that is clinically overseen, with a prescriber reviewing you before each repeat supply, is more likely to produce a sustained result than one where you receive pens without any ongoing check-in. Whether you are considering Wegovy for weight loss in Letchworth or thinking about switching from another treatment, the question to ask is not just what the monthly cost is, but what clinical structure sits around it.

If you want to understand your eligibility (including whether your BMI and any existing health conditions make Wegovy suitable for you) a free consultation with our prescribers is the place to start. Check your eligibility with a free consultation.